<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00204581</url>
  </required_header>
  <id_info>
    <org_study_id>IL-2-LOK-MM</org_study_id>
    <nct_id>NCT00204581</nct_id>
  </id_info>
  <brief_title>Intralesional Treatment With Interleukin-2 (Proleukin) in Soft Tissue Melanoma Metastases</brief_title>
  <official_title>Intralesional Treatment With Interleukin-2 (Proleukin) in Soft Tissue Melanoma Metastases. A Phase II, Prospective, Open, Multicenter Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University Hospital Tuebingen</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University Hospital Tuebingen</source>
  <brief_summary>
    <textblock>
      The intra-/perilesional application of interleukin-2 seems to be a safe and effective
      treatment of skin and soft tissue metastases in malignant melanoma. Especially in case of
      intransit metastases the overall survival rate is still 20-30%.

      However, the management of intransit metastases is sometimes difficult because of frequent
      recurrences. IL-2 intralesionally seems to be an non-invasive option as pilot studies
      indicate. In this study the safety and efficacy of IL-2 are evaluated.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>August 2003</start_date>
  <completion_date type="Actual">December 2009</completion_date>
  <primary_completion_date type="Actual">January 2009</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Efficacy in regard to complete and partial response</measure>
    <time_frame>4 weeks</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Overall survival</measure>
    <time_frame>every 6 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Side-effects</measure>
    <time_frame>during treament and 4 weeks afterwards</time_frame>
  </secondary_outcome>
  <enrollment type="Actual">51</enrollment>
  <condition>Melanoma</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Interleukin-2 (Proleukin)</intervention_name>
    <description>6-12 MIE/d 3times a week</description>
    <other_name>Proleukin</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Age 18+

          -  Informed consent

          -  Histologically proven melanoma

          -  Have confirmed stage IIIB or stage IV disease (AJCC 2002) with skin or soft-tissue
             metastases

        Exclusion Criteria:

          -  Pregnant or lactating women

          -  Patients with severe cardiac disease (e.g. NYHA Functional Class III or IV, myocardial
             infarction within 6 months, ventricular tachyarrhythmias requiring ongoing treatment,
             unstable angina)

          -  Patients with severe liver disease or severe renal disease

          -  Simultaneous immunosuppressive treatment (e.g. steroids)

          -  Simultaneous chemotherapy

          -  Pretreated soft-tissue or skin metastases (e.g. cryo-, radiotherapy)
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Claus Garbe, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Skin Cancer Program, Department of Dermatology, University Hospital Tübingen</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Skin Cancer Program, Department of Dermatology, Liebermeisterstrasse 8</name>
      <address>
        <city>Tübingen</city>
        <state>BW</state>
        <zip>72076</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Germany</country>
  </location_countries>
  <link>
    <url>http://www.ncbi.nlm.nih.gov/pubmed/20564107</url>
    <description>Link to published abstract</description>
  </link>
  <reference>
    <citation>Radny P, Caroli UM, Bauer J, Paul T, Schlegel C, Eigentler TK, Weide B, Schwarz M, Garbe C. Phase II trial of intralesional therapy with interleukin-2 in soft-tissue melanoma metastases. Br J Cancer. 2003 Nov 3;89(9):1620-6.</citation>
    <PMID>14583759</PMID>
  </reference>
  <verification_date>February 2009</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>September 13, 2005</study_first_submitted>
  <study_first_submitted_qc>September 13, 2005</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 20, 2005</study_first_posted>
  <last_update_submitted>August 18, 2011</last_update_submitted>
  <last_update_submitted_qc>August 18, 2011</last_update_submitted_qc>
  <last_update_posted type="Estimate">August 19, 2011</last_update_posted>
  <responsible_party>
    <name_title>Skin Cancer Programme</name_title>
    <organization>Dept. of Dermatology</organization>
  </responsible_party>
  <keyword>Melanoma</keyword>
  <keyword>Soft tissue metastases</keyword>
  <keyword>Interleukin-2</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Melanoma</mesh_term>
    <mesh_term>Neoplasm Metastasis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Aldesleukin</mesh_term>
    <mesh_term>Interleukin-2</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

